Immunordic ApS: Financial statements 2023
CVR: 43773070
Source: annual report 2023, Danish Business Authority
12/01/2023 – 31/12/2023
Immunordic ApS (CVR 43773070) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 540,638 and a net result of DKK -48,678. Equity in the 2023 report amounted to DKK -8,678. The company had 2 employees in the financial year.
- Gross Profit
- DKK 540,638
- Profit/Loss
- DKK -48,678
- Equity
- DKK -8,678
- Total Assets
- DKK 1,054,237
- Employees
- 2
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of January 12, 2023, Emil Arvedsen is registered as director of Immunordic ApS.
As of January 12, 2023, Jannik Faliu is registered as director of Immunordic ApS.
Immunordic ApS was founded on January 12, 2023.
About Immunordic ApS
Immunordic ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Synobody ApS. The management consists of Emil Arvedsen and Jannik Faliu. The company is owned by Arvedsen & Faliu Holding ApS. According to the 2025 annual report, the company had an average of 5 employees. In 2025, the company reported a gross profit of DKK 2,352,263 and a net result of DKK -292,800 compared with DKK 7,762 the year before. Equity in the 2025 report amounted to DKK 606,284.